Selective Wild-Type c-KIT Inhibitors for Mast Cell Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mast cell-mediated disorders such as chronic urticaria and asthma are inadequate, as they do not effectively target mast cells and often result in significant side effects due to non-selective inhibition of c-kit kinase.
Innovation Solution
Development of novel compounds that are selective inhibitors of wild type c-kit kinase, with minimal CNS penetration, to provide targeted treatment for mast cell-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective c-kit kinase inhibition is used to treat mast cell-mediated disorders, then broad kinase inhibition is achieved, but significant side effects occur due to off-target signaling activity
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I with particular Ring A, Ra, R1, R9 substituents) that confer selective affinity for wild type c-kit kinase over other kinases. This structural specificity enables the inhibitor to target only the desired enzyme, producing therapeutic effects without the broad off-target inhibition that causes side effects.
Solution Approach 2:
The patent employs parameter changes by optimizing physical and chemical properties of the inhibitor compounds, including their binding affinity parameters for c-kit kinase, oral bioavailability parameters, and CNS penetration parameters. By adjusting these parameters, the compounds achieve potent inhibition of wild type c-kit while minimizing CNS side effects through reduced brain penetration.
2Object-affected harmful factors
If selective c-kit inhibition is developed to reduce side effects, then off-target signaling activity is reduced, but compound selectivity and potency must be precisely optimized
Solution Approach 1:
The patent uses local quality by incorporating specific functional groups and substituent patterns in the molecular structure (such as tetrazole or triazole rings with particular alkyl and heterocyclic substituents) that create precise spatial and electronic interactions with the wild type c-kit kinase active site. This localized structural design ensures high selectivity while maintaining potent inhibition.
Solution Approach 2:
The patent replaces non-selective kinetic inhibition with a highly selective molecular recognition mechanism. The compounds utilize specific non-covalent interactions (hydrogen bonding, pi-stacking, hydrophobic effects) between the inhibitor structure and the wild type c-kit kinase binding pocket, substituting brute-force inhibition with precision molecular targeting.
3Object-affected harmful factors
If compounds with minimal CNS penetration are designed, then CNS side effects are reduced, but oral bioavailability and brain penetration parameters must be carefully balanced
Solution Approach 1:
The patent applies parameter changes by modifying physicochemical properties of the compounds, such as molecular weight, lipophilicity (logP), and hydrogen bonding capacity, to control CNS penetration. By adjusting these parameters within specific ranges, the compounds achieve optimal oral bioavailability while maintaining low brain penetration to minimize CNS side effects.
Solution Approach 2:
The patent uses pharmacokinetic properties as intermediaries to decouple therapeutic efficacy from CNS side effects. The compounds are designed with specific absorption, distribution, metabolism, and excretion (ADME) characteristics that allow them to reach systemic circulation effectively for therapeutic action while being excluded from or rapidly cleared from the CNS compartment.
Data Source
AI summary
Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein.Compounds of Formula (I) are useful for inhibiting wild type c-kit kinase and for treating disorders and diseases mediated by wild type c-kit kinase in humans or non-humans.